BRÈVE

sur VALBIOTIS (EPA:ALVAL)

Valbiotis Secures New Financing to Bolster Commercial Growth

Graphique de l'évolution du cours de l'action VALBIOTIS (EPA:ALVAL).

On November 16, 2026, Valbiotis, a French laboratory focused on cardiometabolic health, announced a significant financial boost. The company has secured €1.65 million in non-dilutive bank loans from Société Générale, BNP Paribas, and Bpifrance. Additionally, a factoring agreement with BNP Paribas Factor has been established. These financial resources aim to support the expansion of Valbiotis' commercial activities, particularly in pharmacies, without diluting shareholder value.

The new financing includes two loans of €600,000 each from Société Générale and BNP Paribas, both on four-year terms, and a €450,000 loan from Bpifrance with an eight-year term. This arrangement demonstrates the confidence of long-term financial partners in Valbiotis' growth strategy.

Supplementing an existing cash reserve of €11.7 million as of June 30, 2026, these funds enable Valbiotis to prioritize the commercialization of its products while ensuring financial agility. The company aims for a robust international presence in the cardiometabolic health arena.

R. P.

Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de VALBIOTIS